[Form 4] Hims & Hers Health, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported an open-market sale of Class A common stock. On 09/29/2025 she disposed of 2,637 shares at $58.79 per share pursuant to a Rule 10b5-1 trading plan adopted August 28, 2024. After the sale she beneficially owned 163,767 shares, held directly. The Form 4 was filed by one reporting person and signed on behalf of the reporting person by an attorney-in-fact on 09/30/2025. The filing discloses no derivative transactions and provides no financial performance or forward-looking statements.

Positive

• Sale executed under a Rule 10b5-1 trading plan, which provides governance and reduces likelihood the trade was based on undisclosed information
• Timely reporting: transaction and Form 4 filing include dates and attorney-in-fact signature

Negative

• None.

Insights

Securities Analyst

TL;DR: Insider sale under a pre-established 10b5-1 plan; modest-sized disposition leaving substantial remaining ownership.

The reported sale of 2,637 Class A shares at $58.79 was effected under a Rule 10b5-1 plan, which indicates the trades were pre-scheduled and not necessarily contemporaneous with material nonpublic information. The remaining direct beneficial ownership of 163,767 shares is disclosed, and no derivatives are reported. This Form 4 is a routine insider transaction filing and does not include company operational or financial metrics.

Corporate Governance Expert

TL;DR: Corporate officer complied with Section 16 reporting via timely Form 4; trade implemented through governed 10b5-1 plan.

The filing identifies the reporting person as an officer (Chief Legal Officer) and shows the sale was conducted pursuant to a 10b5-1 trading plan adopted on August 28, 2024. The Form indicates single-person filing, provides transaction date and post-sale ownership, and is signed by an attorney-in-fact, meeting signature requirements. No amendments or additional terms of the plan are disclosed in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Boughton Soleil

(Last) (First) (Middle)

2269 CHESTNUT STREET, #523

(Street)

SAN FRANCISCO CA 94123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Hims & Hers Health, Inc. [ HIMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	09/29/2025		S(1)		2,637	D	$58.79	163,767	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024 by the Reporting Person.

Remarks:

	/s/ Kimberly Mather, Attorney-in-Fact for Soleil Boughton	09/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Soleil Boughton report for HIMS?

She reported a sale of 2,637 Class A shares on 09/29/2025 at $58.79 per share.

Was the sale part of a planned trading arrangement for HIMS insider?

Yes. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2024.

How many HIMS shares does Soleil Boughton beneficially own after the sale?

The Form 4 reports she beneficially owned 163,767 shares following the reported transaction.

Did the Form 4 report any derivative transactions for HIMS insiders?

No. The filing discloses no derivative securities acquired, disposed of, or beneficially owned.

Who signed the Form 4 for Soleil Boughton?

The form was signed by Kimberly Mather, Attorney-in-Fact on 09/30/2025.